LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
LISATA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.00−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $9.11M
- P/E (TTM)
- –
- Dividend yield
- –
LISATA THERAPEUTICS, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2016 | FY2015 | FY2014 | FY2013 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $170.00K | $1.00M | $0 | – | – | – | – | – | 100.0% | -83.0% |
| R&D Segment [Member] | – | – | – | – | $14.00K | $154.40K | – | – | – | – |
| PCT Segment [Member] | – | – | – | – | $35.27M | $22.33M | – | – | – | – |
| NeoStem, Inc. [Member] | – | – | – | – | – | – | $17.94M | $14.67M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2016 | FY2015 | FY2014 | FY2013 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | -$18.21M | -$22.41M | -$25.71M | – | – | – | – | – | -18.7% |
| R&D Segment [Member] | – | – | – | – | -$29.50M | -$112.18M | – | – | – |
| PCT Segment [Member] | – | – | – | – | -$1.83M | -$1.67M | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Lisata Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.